LOS ANGELES WIRE   |

November 22, 2026

LA Wire

LOS ANGELES WIRE   |

November 22, 2026
Sirolimus-Coated Balloon Strategy Meets Noninferiority Criterion for Target Lesion Failure Versus Everolimus-Eluting Stents at 12 Months in Multinational TRANSFORM II Study

Sirolimus-Coated Balloon Strategy Meets Noninferiority Criterion for Target Lesion Failure Versus Everolimus-Eluting Stents at 12 Months in Multinational TRANSFORM II Study

By: Natalie Johnson Late-breaking data presented at TCT 2026 compare the MagicTouch Sirolimus Coated Balloon strategy, with bailout stenting when needed, against everolimus-eluting stents in patients with de novo lesions in native coronary arteries. Tampa, Florida, November 1, 2026. In the randomised TRANSFORM II trial, a sirolimus-coated balloon (SCB)